NCT07706075Not yet recruitingPhase 4
Comparing Two Heart Medicines for Fast, Irregular Heartbeat (Atrial Fibrillation)
Verapamil Versus Metoprolol for Rate Control in Hemodynamically Stable Atrial Fibrillation With Rapid Ventricular Response
Source: ClinicalTrials.gov · Last updated 3 Aug 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn whether intravenous verapamil or intravenous metoprolol controls heart rate more effectively in adult patients who arrive at the emergency department with atrial fibrillation and a fast heart rate (rapid ventricular response), but who are otherwise medically stable. Atrial fibrillation with a rapid heart rate is a common emergency, and doctors currently choose between these two standard medicines based on personal preference rather than strong local evidence, since there is limited research on this comparison in Pakistani patients. The main questions this study aims to answer are: Does a higher proportion of patients reach a target heart rate of less than 110 beats per minute within 30 minutes with verapamil compared to metoprolol? Which medicine controls the heart rate faster, on average? Are there differences in side effects (such as low blood pressure, slow heart rate, or breathing problems) between the two medicines? Researchers will compare a group of patients receiving verapamil to a group receiving metoprolol to see if one medicine controls the heart rate faster and more safely than the other. Participants will: 1. Receive either verapamil or metoprolol through an IV, with the dose given according to standard protocols 2. Have their heart rate, blood pressure, and oxygen levels monitored continuously for 30 minutes after the medicine is given 3. Be observed for any side effects during this monitoring period Both medicines used in this study are already standard, guideline-recommended treatments for this condition, so participation will not change or delay the medical care patients would normally receive.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 10 Jul 2026
- Start date
- 1 Jan 2027
- Primary completion date
- 1 Jul 2027
- Lead sponsor
- Muhammad Ali Javed
- Diseases
- Atrial fibrillation
- NCT number
- NCT07706075
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 120
- From 1 Jan 2027 to the primary completion date, 1 Jul 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hemodynamic instability, cardiogenic shock, or acute decompensated heart failure
- Known pre-excitation syndrome (e.g., Wolff-Parkinson-White syndrome) on baseline ECG
- Known hypersensitivity or contraindication to verapamil or metoprolol
- Major bradycardia (heart rate less than 50 bpm) or AV block (second or third degree) on baseline ECG
- Active bronchospasm or severe obstruction of pulmonary disease
Lab values
- Severe left ventricular systolic dysfunction (ejection fraction less than 30%) as determined by echocardiography
- Patients already taking rate control agents (beta-blockers, calcium channel blockers, or digoxin) in the last 24 hours
- Severe hepatic impairment (Child-Pugh Class C) or acute renal failure (eGFR \<15 mL/min/1.73 m²)
Other
- Pregnancy or breastfeeding
- Inability to give informed consent
Who the study is looking for
- Adult patients aged 18 years and above presenting to the Emergency Department
- Confirmed diagnosis of atrial fibrillation with rapid ventricular response (heart rate ≥110 bpm) on 12-lead ECG
- Hemodynamically stable at the time of enrollment (systolic blood pressure ≥90 mmHg, no shock, no acute pulmonary edema)
- Willingness to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.